These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 8640766)
1. Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol). Dumontet C; Duran GE; Steger KA; Beketic-Oreskovic L; Sikic BI Cancer Res; 1996 Mar; 56(5):1091-7. PubMed ID: 8640766 [TBL] [Abstract][Full Text] [Related]
2. MDR 1 activation is the predominant resistance mechanism selected by vinblastine in MES-SA cells. Chen GK; Durán GE; Mangili A; Beketic-Oreskovic L; Sikic BI Br J Cancer; 2000 Oct; 83(7):892-8. PubMed ID: 10970691 [TBL] [Abstract][Full Text] [Related]
3. Cross-resistance to the synthetic retinoid CD437 in a paclitaxel-resistant human ovarian carcinoma cell line is independent of the overexpression of retinoic acid receptor-gamma. Kumar A; Soprano DR; Parekh HK Cancer Res; 2001 Oct; 61(20):7552-5. PubMed ID: 11606393 [TBL] [Abstract][Full Text] [Related]
4. Study of multi-drug resistant mechanisms in a taxol-resistant hepatocellular carcinoma QGY-TR 50 cell line. Zhou J; Cheng SC; Luo D; Xie Y Biochem Biophys Res Commun; 2001 Feb; 280(5):1237-42. PubMed ID: 11162660 [TBL] [Abstract][Full Text] [Related]
5. Prevalence of multidrug resistance related to activation of the mdr1 gene in human sarcoma mutants derived by single-step doxorubicin selection. Chen KG; Jaffrézou JP; Fleming WH; Durán GE; Sikic BI Cancer Res; 1994 Sep; 54(18):4980-7. PubMed ID: 7915196 [TBL] [Abstract][Full Text] [Related]
6. Protein kinase C isoform expression and activity alter paclitaxel resistance in vitro. Chen L; Burger RA; Zaunbrecher GM; Cheng H; Lincoln AJ; Mallarino MC; Monk BJ; Khan SA Gynecol Oncol; 1999 Feb; 72(2):171-9. PubMed ID: 10021296 [TBL] [Abstract][Full Text] [Related]
7. Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Mozzetti S; Ferlini C; Concolino P; Filippetti F; Raspaglio G; Prislei S; Gallo D; Martinelli E; Ranelletti FO; Ferrandina G; Scambia G Clin Cancer Res; 2005 Jan; 11(1):298-305. PubMed ID: 15671559 [TBL] [Abstract][Full Text] [Related]
8. Analysis of tubulin isotypes and mutations from taxol-resistant cells by combined isoelectrofocusing and mass spectrometry. Verdier-Pinard P; Wang F; Martello L; Burd B; Orr GA; Horwitz SB Biochemistry; 2003 May; 42(18):5349-57. PubMed ID: 12731876 [TBL] [Abstract][Full Text] [Related]
9. Combretastatin A-4 resistance in H460 human lung carcinoma demonstrates distinctive alterations in beta-tubulin isotype expression. Wehbe H; Kearney CM; Pinney KG Anticancer Res; 2005; 25(6B):3865-70. PubMed ID: 16309172 [TBL] [Abstract][Full Text] [Related]
10. The acridonecarboxamide GF120918 potently reverses P-glycoprotein-mediated resistance in human sarcoma MES-Dx5 cells. Traunecker HC; Stevens MC; Kerr DJ; Ferry DR Br J Cancer; 1999 Nov; 81(6):942-51. PubMed ID: 10576649 [TBL] [Abstract][Full Text] [Related]
11. Tumor cells resistant to a microtubule-depolymerizing hemiasterlin analogue, HTI-286, have mutations in alpha- or beta-tubulin and increased microtubule stability. Poruchynsky MS; Kim JH; Nogales E; Annable T; Loganzo F; Greenberger LM; Sackett DL; Fojo T Biochemistry; 2004 Nov; 43(44):13944-54. PubMed ID: 15518543 [TBL] [Abstract][Full Text] [Related]
12. Direct analysis of tubulin expression in cancer cell lines by electrospray ionization mass spectrometry. Verdier-Pinard P; Wang F; Burd B; Angeletti RH; Horwitz SB; Orr GA Biochemistry; 2003 Oct; 42(41):12019-27. PubMed ID: 14556633 [TBL] [Abstract][Full Text] [Related]
13. SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells. George JA; Chen T; Taylor CC Cancer Res; 2005 Nov; 65(22):10381-8. PubMed ID: 16288028 [TBL] [Abstract][Full Text] [Related]
14. Modulation of endogenous beta-tubulin isotype expression as a result of human beta(III)cDNA transfection into prostate carcinoma cells. Ranganathan S; McCauley RA; Dexter DW; Hudes GR Br J Cancer; 2001 Sep; 85(5):735-40. PubMed ID: 11531260 [TBL] [Abstract][Full Text] [Related]
15. Cross-resistance of vinblastine- and taxol-resistant mutants of Chinese hamster ovary cells to other anticancer drugs. Gupta RS Cancer Treat Rep; 1985 May; 69(5):515-21. PubMed ID: 2860971 [TBL] [Abstract][Full Text] [Related]
16. Expression of beta-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCI-Anticancer Drug Screen: correlation with sensitivity to microtubule active agents. Nicoletti MI; Valoti G; Giannakakou P; Zhan Z; Kim JH; Lucchini V; Landoni F; Mayo JG; Giavazzi R; Fojo T Clin Cancer Res; 2001 Sep; 7(9):2912-22. PubMed ID: 11555610 [TBL] [Abstract][Full Text] [Related]
17. The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells. Kowalski RJ; Giannakakou P; Gunasekera SP; Longley RE; Day BW; Hamel E Mol Pharmacol; 1997 Oct; 52(4):613-22. PubMed ID: 9380024 [TBL] [Abstract][Full Text] [Related]
18. Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. Mechetner E; Kyshtoobayeva A; Zonis S; Kim H; Stroup R; Garcia R; Parker RJ; Fruehauf JP Clin Cancer Res; 1998 Feb; 4(2):389-98. PubMed ID: 9516927 [TBL] [Abstract][Full Text] [Related]
19. Increased levels of tyrosinated alpha-, beta(III)-, and beta(IV)-tubulin isotypes in paclitaxel-resistant MCF-7 breast cancer cells. Banerjee A Biochem Biophys Res Commun; 2002 Apr; 293(1):598-601. PubMed ID: 12054644 [TBL] [Abstract][Full Text] [Related]
20. Increase of beta(III)- and beta(IVa)-tubulin isotopes in human prostate carcinoma cells as a result of estramustine resistance. Ranganathan S; Dexter DW; Benetatos CA; Chapman AE; Tew KD; Hudes GR Cancer Res; 1996 Jun; 56(11):2584-9. PubMed ID: 8653701 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]